Trial intelligence / Profile preview

Phase III lebrikizumab in adolescents with uncontrolled asthma on ICS plus second controller

jRCT2080223137Phase 3

Sponsor
Chugai Pharmaceutical Co., Ltd.
Start
Mar 2016
Modality
Monoclonal Antibodies → Antibody-Based Therapeutics
Countries
1
01

Overview

Phase 3, randomised, double-blind trial of lebrikizumab in asthma (3 arms), sponsored by Chugai Pharmaceutical Co., Ltd.

02

Drugs

lebrikizumab
03

Conditions

asthma

Beyond the preview

Go deeper on jRCT2080223137.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on jRCT2080223137.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call